Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SPR300
- Development stage
- Phase 1
- Lead developer
- Futura Medical
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
**SPR300** is an investigational fixed-dose topical analgesic gel developed by Futura Medical. Public sources identify it as a methyl salicylate + menthol formulation, reported to use Futura's DermaSys skin-delivery technology. It was evaluated in a randomized, double-blind Phase 1 crossover study in healthy volunteers using a UV-induced inflammatory-pain model; no marketed brand name or later-stage clinical development has been confirmed. ([hra.nhs.uk](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/study-to-compare-efficacy-and-safety-of-topical-dcf100-tib200spr300/))
- Other names
- methyl salicylate + menthol
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)TRPA1 (Transient receptor potential cation channel subfamily A member 1)TRPM8 (Transient receptor potential cation channel subfamily M member 8)
Beyond the preview
Go deeper on SPR300.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SPR300.